Data gathered: April 15
AI Stock Analysis - Genelux (GNLX)
Analysis generated October 5, 2024. Powered by Chat GPT.
Genelux Corporation is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of cancer. The firm has employed its proprietary technology to develop oncolytic virus-based biotherapeutics, aiming to provide innovative solutions to unmet medical needs in oncology. As of the most recent data update, the company has shown a mixed performance across multiple metrics, making a comprehensive analysis crucial for potential investors.
Stock Alerts - Genelux (GNLX)
 |
Genelux | April 14 Price is up by 7.1% in the last 24h. |
|
Genelux | April 10 Price is up by 6.3% in the last 24h. |
|
Genelux | April 9 Price is up by 8.7% in the last 24h. |
|
Genelux | April 8 Price is up by 5.1% in the last 24h. |
Alternative Data for Genelux
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 426 | Sign up | Sign up | Sign up |
| Twitter Followers | 106 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 31 | Sign up | Sign up | Sign up |
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
| Price | $2.42 |
| Target Price | Sign up |
| Volume | 157,630 |
| Market Cap | $93M |
| Year Range | $1.93 - $5.66 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Brookline Capital Management Estimates Genelux Q1 EarningsApril 4 - ETF Daily News |
|
HC Wainwright Has Negative Outlook for Genelux Q1 EarningsApril 3 - ETF Daily News |
|
HC Wainwright Reaffirms “Buy” Rating for Genelux (NASDAQ:GNLX)April 1 - ETF Daily News |
|
Brokers Offer Predictions for Genelux FY2024 EarningsMarch 29 - ETF Daily News |
|
Brookline Capital Management Forecasts Genelux Q1 EarningsMarch 28 - ETF Daily News |
|
FY2024 Earnings Estimate for Genelux Issued By HC WainwrightMarch 28 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 2.9M | -2.9M | -6.5M | -6.2M | -0.190 |
| Q2 '24 | 0 | 2.5M | -2.5M | -6.6M | -6.4M | -0.220 |
| Q1 '24 | 8,000 | 4.1M | -4.1M | -7.9M | -7.6M | -0.290 |
| Q4 '23 | 1.5M | 2.8M | -2.8M | -6.8M | -6.6M | -0.250 |
| Q3 '23 | 0 | 2.5M | -2.5M | -5.3M | -5.1M | -0.200 |
Insider Transactions View All
| Tyree James L filed to sell 45,791 shares at $2.5. December 30 '24 |
| Cappello Joseph filed to sell 14,653 shares at $2.3. December 18 '24 |
| Smalling Ralph filed to sell 16,322 shares at $2.3. December 18 '24 |
| Zak Lourie S. filed to sell 40,802 shares at $2.3. December 18 '24 |
| Zindrick Thomas filed to sell 37,372 shares at $2.3. December 18 '24 |
Similar companies
Read more about Genelux (GNLX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Genelux?
The Market Cap of Genelux is $93M.
What is the current stock price of Genelux?
Currently, the price of one share of Genelux stock is $2.42.
How can I analyze the GNLX stock price chart for investment decisions?
The GNLX stock price chart above provides a comprehensive visual representation of Genelux's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Genelux shares. Our platform offers an up-to-date GNLX stock price chart, along with technical data analysis and alternative data insights.
Does GNLX offer dividends to its shareholders?
As of our latest update, Genelux (GNLX) does not offer dividends to its shareholders. Investors interested in Genelux should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Genelux?
Some of the similar stocks of Genelux are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.